{"id":"W2098499757","doi":"10.1016/s1470-2045(12)70509-0","title":"Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial","year":2012,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":526,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Genentech","keywords":"Bevacizumab; Medicine; Oxaliplatin; Capecitabine; Colorectal cancer; Clinical endpoint; Internal medicine; Bolus (digestion); Chemotherapy; Fluorouracil; Surgery; Gastroenterology; Phases of clinical research; Randomized controlled trial; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005724936,0.0003156507,0.002027873,0.00005234278,0.0002471486,0.00001157534,0.0001048627,0.0001398992,0.0005713242],"category_scores_gemma":[0.0001673746,0.0001629429,0.0004074061,0.00007710455,0.0001460515,0.00003226633,0.00001565423,0.0001187245,0.00002036922],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001428075,"about_ca_system_score_gemma":0.0008154335,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002554028,"about_ca_topic_score_gemma":0.0003901502,"domain_scores_codex":[0.9982659,0.0002155134,0.0004223484,0.0002643183,0.0001818896,0.0006499903],"domain_scores_gemma":[0.9978201,0.001327491,0.0002780635,0.0003180887,0.0001073486,0.0001488621],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9428982,0.002180911,0.0001455033,0.00002760546,0.001502522,0.00001388905,0.002128883,0.00001612327,0.001051028,0.00006888897,0.003870051,0.04609637],"study_design_scores_gemma":[0.8285955,0.01749676,0.0002163139,0.00002242246,0.001284634,0.0000149775,0.000150088,0.0005906598,0.001529209,0.00003741248,0.1499196,0.0001423801],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9556504,0.004255192,0.00005598793,0.01802345,0.001551476,0.01480889,0.0001053399,0.00009409279,0.005455208],"genre_scores_gemma":[0.9728013,0.0009471041,0.0002663637,0.003913471,0.003305107,0.01611023,0.00005197626,0.00003811669,0.002566319],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1460496,"threshold_uncertainty_score":0.6644619,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0801800099192156,"score_gpt":0.4280330432983145,"score_spread":0.3478530333790989,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}